Growth rate-corrected (GR) dose-response metric signatures across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 3 of 4: Median, upper quartile, and lower quartile GR metrics per perturbagen. - Dataset (ID:20270)
Download: Excel (XLSX), Comma-separated (CSV)
Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | GR50 lower quartile | GR50 median | GR50 upper quartile | GRmax lower quartile | GRmax median | GRmax upper quartile | GRinf lower quartile | GRinf median | GRinf upper quartile | Hill Coefficient lower quartile | Hill Coefficient median | Hill Coefficient upper quartile | GR_AOC lower quartile | GR_AOC median | GR_AOC upper quartile | GEC50 lower quartile | GEC50 median | GEC50 upper quartile |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ribavirin | N/A | N/A | 100.0000 | 100.0000 | 100.0000 | 0.6045 | 0.7146 | 0.9546 | 0.4725 | 0.6701 | 0.9546 | 0.0000 | 0.0000 | 0.9838 | 0.0119 | 0.0416 | 0.0703 | 50.4745 | 100.0000 | 100.0000 | |
Carboplatin | DNA cross-linker | DNA cross-linker | 30.4522 | 52.4276 | 91.0569 | -0.9081 | -0.7672 | -0.5844 | -0.9460 | -0.8644 | -0.7390 | 1.2433 | 1.6402 | 2.1619 | 0.2714 | 0.3706 | 0.4859 | 52.1319 | 91.7409 | 100.0000 | |
Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 36.5873 | 68.4588 | 100.0000 | -0.7737 | -0.2023 | 0.2203 | -0.7439 | -0.3900 | 0.2345 | 0.6570 | 1.9429 | 3.4993 | 0.1339 | 0.2188 | 0.2978 | 54.8881 | 71.4700 | 100.0000 | |
Dichloroacetate | PDK | PDK | 100.0000 | 100.0000 | 100.0000 | 0.8082 | 0.8801 | 0.9216 | 0.7946 | 0.8670 | 0.9296 | 0.0000 | 0.0000 | 0.2064 | 0.0234 | 0.0440 | 0.0744 | 58.3872 | 100.0000 | 100.0000 | |
PD184352 | MEK | MAPK | 31.0822 | 100.0000 | 100.0000 | 0.4258 | 0.7584 | 0.9084 | -0.2272 | 0.7139 | 0.9084 | 0.0000 | 0.0524 | 0.4766 | 0.0368 | 0.0888 | 0.1432 | 63.7076 | 100.0000 | 100.0000 | |
FR180204 | ERK1/2 | MAPK | 56.2203 | 100.0000 | 100.0000 | 0.4862 | 0.6317 | 0.8238 | -0.1433 | 0.2500 | 0.7055 | 0.0180 | 0.6403 | 1.9539 | 0.0470 | 0.0722 | 0.1058 | 65.9938 | 100.0000 | 100.0000 | |
Ibandronate | FDPS | N/A | 49.3295 | 82.7741 | 100.0000 | -0.5209 | -0.1213 | 0.0387 | -0.7048 | -0.2169 | -0.0113 | 0.9599 | 1.4483 | 1.9155 | 0.2062 | 0.2750 | 0.3199 | 66.6332 | 98.6899 | 100.0000 | |
Nilotinib | ABL | nRTK | 100.0000 | 100.0000 | 100.0000 | 0.7849 | 0.9109 | 1.0055 | 0.7841 | 0.9109 | 1.0055 | 0.0000 | 0.0000 | 0.7234 | 0.0029 | 0.0487 | 0.0775 | 73.6076 | 100.0000 | 100.0000 | |
CGC-11047 | Polyamine analogue | N/A | 43.1451 | 85.4630 | 100.0000 | -0.8722 | -0.7234 | -0.2437 | -1.0000 | -0.9172 | -0.4365 | 0.4134 | 0.5735 | 1.1488 | 0.3172 | 0.3971 | 0.4905 | 94.6485 | 100.0000 | 100.0000 | |
5-DFUR | TYMS | TYMS | 68.5295 | 100.0000 | 100.0000 | -0.1871 | -0.0208 | 0.0399 | -0.5625 | -0.3158 | -0.1425 | 0.3943 | 0.5084 | 0.6195 | 0.2584 | 0.3100 | 0.3856 | 100.0000 | 100.0000 | 100.0000 | |
PS-1145 | IKK | NFKB | 100.0000 | 100.0000 | 100.0000 | 0.8452 | 0.9304 | 0.9718 | 0.8353 | 0.9304 | 0.9695 | 0.0000 | 0.0000 | 0.8067 | -0.0033 | 0.0200 | 0.0533 | 100.0000 | 100.0000 | 100.0000 | |
5-FU | TYMS | TYMS | 43.5628 | 98.8715 | 100.0000 | -0.6126 | -0.4736 | -0.0711 | -0.8532 | -0.6532 | -0.1200 | 0.5225 | 0.5967 | 0.7832 | 0.3295 | 0.4853 | 0.6100 | 100.0000 | 100.0000 | 100.0000 | |
FTase Inhibitor I | Ftase | MAPK | 100.0000 | 100.0000 | 100.0000 | 0.7715 | 0.8851 | 0.9752 | 0.7468 | 0.8851 | 0.9752 | 0.0000 | 0.0000 | 0.0000 | 0.0099 | 0.0556 | 0.0941 | 100.0000 | 100.0000 | 100.0000 | |
Vorinostat | HDAC | HDAC | 72.1503 | 100.0000 | 100.0000 | -0.8970 | -0.8099 | -0.5591 | -0.9320 | -0.8403 | -0.5970 | 1.0273 | 1.3201 | 1.6251 | 0.4794 | 0.5820 | 0.7389 | 100.0000 | 100.0000 | 100.0000 | |
Valproic acid | HDAC | HDAC | 100.0000 | 100.0000 | 100.0000 | -0.8969 | -0.6820 | -0.4277 | -0.5381 | -0.3207 | -0.1180 | 1.1443 | 1.2884 | 1.4704 | 0.1935 | 0.2464 | 0.2891 | 100.0000 | 100.0000 | 100.0000 |